All In Biotech

Drug Trial Radar · NCT05712421

A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism

A Randomized, Double-blind, Dose-Conversion Study to Evaluate the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Subjects With Primary Hypothyroidism Who Are Euthyroid on Levothyroxine Replacement Therapy

Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 303 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

303

Actual

Start

Feb 28, 2023

Primary completion

May 5, 2025

Study completion Sep 18, 2025

Sponsor

Lead sponsor
Neuvosyn Laboratories, LLCIndustry
Sponsor type
Industry
First posted
Feb 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The North Star study is a multi-center, Phase 2, double-blind, randomized, parallel group clinical study to evaluate the safe and effective dose conversion from Levothyroxine to North Star therapy.

Conditions

  • Hypothyroidism

Interventions

  • North StarDrug

    North Star

  • LevothyroxineDrug

    Levothyroxine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The ratio of the LT4 dose (mcg/day) at screening to North Star (mg/day) at the end of the treatment period required to achieve and maintain serum thyroid-stimulating hormone (TSH) levels within the normal reference range.Time frame: Week 30

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Neuvosyn Investigational Site

    Birmingham, Alabama

  • Neuvosyn Investigational Site

    Canoga Park, California

  • Neuvosyn Investigational Site

    Greenbrae, California

  • Neuvosyn Investigational Site

    Toluca Lake, California

  • Neuvosyn Investigational Site

    Farmington, Connecticut

  • Neuvosyn Investigational Site

    Boca Raton, Florida

  • Neuvosyn Investigational Site

    Miami, Florida

  • Neuvosyn Investigational Site

    Miami, Florida

  • Neuvosyn Investigational Site

    Miami, Florida

  • Neuvosyn Investigational Site

    Miami, Florida

  • Neuvosyn Investigational Site

    Miami, Florida

  • Neuvosyn Investigational Site

    Sunrise, Florida

  • Neuvosyn Investigational Site

    Acworth, Georgia

  • Neuvosyn Investigational Site

    Atlanta, Georgia

  • Neuvosyn Investigational Site

    Columbus, Georgia

  • Neuvosyn Investigational Site

    Sugar Hill, Georgia

  • Neuvosyn Investigational Site

    Saginaw, Michigan

  • Neuvosyn Investigational Site

    Gladstone, Missouri

  • Neuvosyn Investigational Site

    Williamsville, New York

  • Neuvosyn Investigational Site

    Denver, North Carolina

  • Neuvosyn Investigational Site

    Winston-Salem, North Carolina

  • Neuvosyn Investigational Site

    Beavercreek, Ohio

  • Neuvosyn Investigational Site

    Columbus, Ohio

  • Neuvosyn Investigational Site

    Georgetown, Texas

  • Neuvosyn Investigational Site

    Houston, Texas

  • Neuvosyn Investigational Site

    Katy, Texas

  • Neuvosyn Investigational Site

    Katy, Texas

  • Neuvosyn Investigational Site

    Lewisville, Texas

  • Neuvosyn Investigational Site

    Paris, Texas

  • Neuvosyn Investigational Site

    Pearland, Texas

  • Neuvosyn Investigational Site

    Stafford, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.